Molecular biology of influenza virus replication and points of action of Inhibitors

  • J. S. Oxford
Part of the Chemotherapy book series (CT, volume 6)


Knowledge of the details of replication of the virus should lead to more logical approaches for the selection of virus Inhibitory compounds. The Influenza virus exists as irregularly shaped particles some 75 to 190 nm in diameter bounded by an outer lipid membrane. The two envelope proteins haemagglutinin (HA) and neuraminidase (NA) take the form of spikes covering the virus surface and attached by one end at the lipid membrane. Internally the particle contains several other components of which the two major ones are the ribonucleoprotein (HP) which is closely associated with the helical RNA genome of the virus and the matrix protein (MP) which underlies the lipid membrane and may form a matrix surrounding the ribonucleoprotein-RNA complex. The polypeptide composition of highly purified Influenza virus preparations has now been established by Polyacrylamide gel electrophoresis studies. Seven polypeptides have been identified in the virus particle with molecular weights ranging from 25,000 to 94,000 daltons.


Influenza Virus Neuraminic Acid Influenza Virus Replication Chemoprophylactic Agent Synthetic Nucleoside Analogue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aoyagi, T. et al. Biochemica et Biophysica Research Communication, 57, 271 (1974).CrossRefGoogle Scholar
  2. Cooper, P.D. et al. Intervirology, 1, 1 (1973).PubMedCrossRefGoogle Scholar
  3. Dourmashkin, R.R. & Tyrrell, D.A.J. Journal of General Virology, 24, 129 (1974).PubMedCrossRefGoogle Scholar
  4. Dowdle, W.R. et al. Journal of Virology, 13, 269 (1974).PubMedGoogle Scholar
  5. Downey, K.M. et al. Biochemica et Biophysica Research Communications, 56, 227 (1974).CrossRefGoogle Scholar
  6. Ho, P.P.K. & Walters, C.P. Annals of the New York Academy of Science, 173, 438 (1971).CrossRefGoogle Scholar
  7. Krug, R.M. & Etkind, P.R. Antimicrobial Agents and Chemotherapy, 334 (1973).Google Scholar
  8. Kuo, C.H. & August, J.T. Nature (New Biology), 227, 105 (1970).CrossRefGoogle Scholar
  9. Oxford, J.S. & Perrin, D.D. Journal of General Virology, 23, 59 (1974)PubMedCrossRefGoogle Scholar
  10. Oxford, J.S. et al. Annals of the New York Academy of Sciences, 173, 300 (1970).CrossRefGoogle Scholar
  11. Palese, P. et al. Virology, 59, 490 (1974).PubMedCrossRefGoogle Scholar
  12. Pons, M.W. Virology, 47, 823 (1972).PubMedCrossRefGoogle Scholar
  13. Sidwell, R.W. et al. Science, 177, 705 (1972).PubMedCrossRefGoogle Scholar
  14. Skehel, J.J. Virology, 49, 23 (1972).PubMedCrossRefGoogle Scholar
  15. Subak-Sharpe, J.H. et al. Nature, 222, 341 (1969).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1976

Authors and Affiliations

  • J. S. Oxford
    • 1
  1. 1.Division of VirologyNational Institute for Medical Research, Mill HillLondonEngland

Personalised recommendations